Revenio Group Corporation: Transfer of the Company's own shares

Revenio Group Corporation has on May 14, 2025, transferred 4,546 Company’s treasury shares (REG1V) to the members of the Board of Directors as part of the remuneration of the Board.

Revenio Group Corporation's AGM decided on April 10, 2025 that approximately 40 percent of the Board members' annual remuneration (gross) will be settled in the form of the company’s shares held in its treasury, however not exceeding a maximum of 7,000 shares in total, while approximately 60 percent will consist of a monetary payment. Tax will be deducted from the monetary payment, calculated on the amount of the entire annual remuneration.

The AGM decided that the Chairman of the Board be entitled to an annual emolument of EUR 60,000, the possible deputy chair of the Board of Directors be entitled to an annual emolument of EUR 45,000, the Board Members be entitled to an annual emolument of EUR 30,000, the chair of the Audit Committee be entitled to an annual emolument of EUR 20,000, the chair of the Nomination and Remuneration Committee be entitled to an annual emolument of EUR 10,000, and the members of the Board Committees be entitled to an annual emolument of EUR 5,000. The share payment will be valued using the weighted average value of the share on the day following the release of the Interim Report January 1- March 31, 2025.

As a result of these transfers, the share-based board member fees have been completely settled for the year 2025. Revenio Group Corporation now holds a total of 77,691 of its treasury shares.

For further information, please contact
Robin Pulkkinen, CFO, tel.  +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.reveniogroup.fi/en 

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2024, the Group’s net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.